vs
Adagio Medical Holdings, Inc.（ADGM）与ANGIODYNAMICS INC（ANGO）财务数据对比。点击上方公司名可切换其他公司
ANGIODYNAMICS INC自由现金流更多（$4.2M vs $-3.5M）
Adagio Medical Holdings, Inc.是一家医疗科技企业，专注于开发和商业化用于治疗包括房颤在内的各类心律失常病症的冷冻消融平台，产品面向电生理临床医师，核心市场覆盖北美及欧洲，致力于提升心律疾病患者的治疗安全性与效果。
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
ADGM vs ANGO — 直观对比
营收规模更大
ANGO
是对方的Infinity倍
$0
自由现金流更多
ANGO
多$7.8M
$-3.5M
损益表 — Q3 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $0 | $79.4M |
| 净利润 | $-10.1M | $-6.3M |
| 毛利率 | — | 56.4% |
| 营业利润率 | — | -7.7% |
| 净利率 | — | -8.0% |
| 营收同比 | — | 9.0% |
| 净利润同比 | -380.6% | 40.9% |
| 每股收益（稀释后） | $-0.66 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADGMANGO
| Q4 25 | — | $79.4M | ||
| Q3 25 | $0 | $75.7M | ||
| Q2 25 | — | $80.2M | ||
| Q1 25 | — | $72.0M | ||
| Q4 24 | — | $72.8M | ||
| Q3 24 | $132.0K | $67.5M | ||
| Q2 24 | $254.0K | $71.0M | ||
| Q1 24 | — | $75.2M |
净利润ADGMANGO
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $-10.1M | $-10.9M | ||
| Q2 25 | — | $-6.0M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | — | $-10.7M | ||
| Q3 24 | $3.6M | $-12.8M | ||
| Q2 24 | $-5.7M | $-13.4M | ||
| Q1 24 | — | $-187.7M |
毛利率ADGMANGO
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 52.7% | ||
| Q1 25 | — | 54.0% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | -213.6% | 54.4% | ||
| Q2 24 | -168.5% | 54.3% | ||
| Q1 24 | — | 47.7% |
营业利润率ADGMANGO
| Q4 25 | — | -7.7% | ||
| Q3 25 | — | -14.1% | ||
| Q2 25 | — | -7.2% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | — | -15.2% | ||
| Q3 24 | -3352.3% | -19.4% | ||
| Q2 24 | -2621.7% | -20.4% | ||
| Q1 24 | — | -265.9% |
净利率ADGMANGO
| Q4 25 | — | -8.0% | ||
| Q3 25 | — | -14.4% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | -14.7% | ||
| Q3 24 | 2731.8% | -19.0% | ||
| Q2 24 | -2257.5% | -18.9% | ||
| Q1 24 | — | -249.7% |
每股收益（稀释后）ADGMANGO
| Q4 25 | — | $-0.15 | ||
| Q3 25 | $-0.66 | $-0.26 | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | $0.02 | $-0.31 | ||
| Q2 24 | $-7.35 | $-0.35 | ||
| Q1 24 | — | $-4.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.7M | $41.6M |
| 总债务越低越好 | $21.2M | — |
| 股东权益账面价值 | $-1.3M | $176.3M |
| 总资产 | $31.5M | $269.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADGMANGO
| Q4 25 | — | $41.6M | ||
| Q3 25 | $4.7M | $38.8M | ||
| Q2 25 | — | $55.9M | ||
| Q1 25 | — | $44.8M | ||
| Q4 24 | — | $54.1M | ||
| Q3 24 | $28.3M | $55.0M | ||
| Q2 24 | — | $76.1M | ||
| Q1 24 | — | $78.5M |
总债务ADGMANGO
| Q4 25 | — | — | ||
| Q3 25 | $21.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
股东权益ADGMANGO
| Q4 25 | — | $176.3M | ||
| Q3 25 | $-1.3M | $178.9M | ||
| Q2 25 | — | $183.0M | ||
| Q1 25 | — | $185.9M | ||
| Q4 24 | — | $186.8M | ||
| Q3 24 | $76.6M | $196.6M | ||
| Q2 24 | $-140.5M | $205.6M | ||
| Q1 24 | — | $218.7M |
总资产ADGMANGO
| Q4 25 | — | $269.7M | ||
| Q3 25 | $31.5M | $265.6M | ||
| Q2 25 | — | $280.1M | ||
| Q1 25 | — | $285.4M | ||
| Q4 24 | — | $291.6M | ||
| Q3 24 | $107.2M | $293.6M | ||
| Q2 24 | $-140.5M | $317.7M | ||
| Q1 24 | — | $324.8M |
负债/权益比ADGMANGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.0M | $4.7M |
| 自由现金流经营现金流 - 资本支出 | $-3.5M | $4.2M |
| 自由现金流率自由现金流/营收 | — | 5.3% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-9.3M |
8季度趋势，按日历期对齐
经营现金流ADGMANGO
| Q4 25 | — | $4.7M | ||
| Q3 25 | $-3.0M | $-15.9M | ||
| Q2 25 | — | $18.8M | ||
| Q1 25 | — | $-13.2M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | $-6.4M | $-18.3M | ||
| Q2 24 | — | $5.0M | ||
| Q1 24 | — | $-12.5M |
自由现金流ADGMANGO
| Q4 25 | — | $4.2M | ||
| Q3 25 | $-3.5M | $-16.6M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $-15.0M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | $-6.9M | $-19.3M | ||
| Q2 24 | — | $4.4M | ||
| Q1 24 | — | $-13.1M |
自由现金流率ADGMANGO
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -22.0% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | -5254.5% | -28.7% | ||
| Q2 24 | — | 6.2% | ||
| Q1 24 | — | -17.5% |
资本支出强度ADGMANGO
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 437.9% | 1.6% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 0.8% |
现金转化率ADGMANGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADGM
暂无分部数据
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
